Women's imaging vendor Hologic and Gen-Probe announced that Carl Hull, chairman and CEO of Gen-Probe, has entered into an agreement to continue his employment with the combined company for a minimum of 15 months.
Hull will serve as senior vice president and general manager of the combined company's diagnostics business, which will include Gen-Probe's current operations, as well as Hologic's diagnostics segment, the two firms said. The companies also confirmed that integration planning efforts are well under way and continue to proceed as planned.
Hologic has launched marketing for $750 million in senior notes in a private offering expected to close concurrently with the completion of the company's acquisition of Gen-Probe, Hologic said. Gen-Probe has scheduled a special meeting of stockholders for July 31 to vote on the pending transaction, which is expected to close on or near August 1, 2012.
